electroCore, Inc. (ECOR)
| Market Cap | 69.25M |
| Revenue (ttm) | 4.48M |
| Net Income (ttm) | -19.09M |
| Shares Out | 48.52M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 431,103 |
| Open | 1.010 |
| Previous Close | 1.000 |
| Day's Range | 0.981 - 1.020 |
| 52-Week Range | 0.905 - 3.630 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 3.27 (+228.1%) |
| Est. Earnings Date | Nov 4, 2021 |
About ECOR
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in R...
Financial Performance
In 2020, electroCore's revenue was $3.50 million, an increase of 46.25% compared to the previous year's $2.39 million. Losses were -$23.51 million, -47.92% less than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for electroCore stock is "Buy." The 12-month stock price forecast is 3.27, which is an increase of 228.12% from the latest price.
News
electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine
Health Canada expands gammaCore label to include the acute and preventive treatment of migraine in adolescents Health Canada expands gammaCore label to include the acute and preventive treatment of migr...
electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
ROCKAWAY, NJ, Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the Cantor...
electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimul...
ROCKAWAY, NJ, Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the SAVIOR-...
electroCore to Participate at Upcoming Investor Conferences
ROCKAWAY, NJ, Sept. 23, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give ...
electroCore Announces New Patent Expanding Claims Related to Delivery of Non-Invasive Vagus Nerve Stimulation Therapy...
ROCKAWAY, NJ, Sept. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office ...
electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal ...
ROCKAWAY, NJ, Sept. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that on September 10, 2021 the company received Sec...
electroCore to Present at the HC Wainwright 23rd Annual Global Investment Conference
ROCKAWAY, NJ, Aug. 31, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a...
electroCore Announces New Reseller Agreement with Red One Medical Devices, LLC.
ROCKAWAY, NJ, Aug. 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced a reseller agreement with Red One Medical Devices, LL...
electroCore Announces Second Quarter 2021 Financial Results
Second quarter 2021 net sales of $1.3 million, increased 69% over second quarter 2020 and 5% sequentially. Company to host a conference call and webcast today, August 5, 2021 at 4:30 pm ET Second quarte...
ElectroCore Analyst: Nerve Stimulation Market Opportunity Is Large
A combination of a large total addressable market, regulatory clearance, strong partnerships and effective product has Ladenburg Thalmann analysts bullish on electroCore, Inc. (NASDAQ:ECOR). The electro...
ElectroCore Stock Is Trading Higher As Ladenburg Initiates Coverage With $3 Price Target, Buy Rating
Ladenburg Thalmann has initiated coverage of ElectroCore Inc (NASDAQ: ECOR) with a Buy rating and $3 price target, implying an upside of around 190%. The Company's gammaCore Sapphire device is currently...
electroCore Announces Issuance of New Patent for Migraine Treatment using Smartphones
ROCKAWAY, NJ, July 27, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (...
electroCore announces Dr. Peter Staats to receive Lifetime Achievement Award from the American Society of Pain and Ne...
ROCKAWAY, NJ, July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical...
electroCore to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
ROCKAWAY, NJ, July 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, CEO will present a company overv...
ElectroCore Stock Dives On $18M Equity Raise Issued At Deep Discount Of 32%
ElectroCore Inc (NASDAQ: ECOR) has priced underwritten public offering of 18 million shares at $1 per share, representing a discount of 32% from the last close price of $1.48 on Tuesday. The gross proce...
electroCore Announces Pricing of $18.0 Million Public Offering of Common Stock
ROCKAWAY, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the pricing of an underwritten publi...
electroCore Announces Proposed Public Offering of Common Stock
ROCKAWAY, NJ, June 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that it intends to offer and sell sha...
electroCore Announces Publication of Study on the Effect of non-invasive Vagus Nerve Stimulation (nVNS) on Cognitive ...
ROCKAWAY, NJ, June 24, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper on June 10,...
electroCore Completes Sale of $1.4 Million of NJ NOL Tax Benefits
ROCKAWAY, NJ, June 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of $1.4 million of its...
electroCore Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcome...
ROCKAWAY, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled ...
electroCore to Present at Investor Conferences in June
ROCKAWAY, NJ, May 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced today that its management team will present a several invest...
electroCore, Inc. Celebrates Veterans and Active Members of the Military During National Military Appreciation Month
ROCKAWAY, N.J.--(BUSINESS WIRE)--National Military Appreciation Month commemorates and expresses gratitude for the sacrifices current and former members of the U.S. armed forces have made for our countr...
electroCore Supports Results of Lancet Paper Highlighting the Benefits of Vagus Nerve Stimulation for Stroke Patients
ROCKAWAY, N.J.--(BUSINESS WIRE)--electroCore, Inc., a commercial-stage bioelectronic medicine company, commends the results of the VNS-REHAB study published in the April 24th edition of The Lancet which...
electroCore Announces First Quarter 2021 Financial Results
Record First quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020 and 30% sequentially